News

7,500 Patients Given Genetic Testing, Counseling via PD GENEration

The PD GENEration study is halfway to its goal of providing free genetic testing and counseling to 15,000 people with Parkinson’s disease, with 7,500 patients included in the effort to date. “Ensuring that the entire Parkinson’s community — including the 90,000 individuals expected to receive a PD [Parkinson’s…

Exergame-based Program Shown to Be Feasible for Parkinson’s Rehab

A cognitive-motor training program featuring a video game platform that promotes exercise is feasible for people with Parkinson’s disease to use, a new study demonstrates. Patients using the program along with standard rehabilitation showed comparable and greater motor and cognitive improvements relative to those on standard rehabilitation alone. These preliminary…

Community Exercise May Help to Ease Parkinson’s Motor Symptoms

Taking part in a community-based exercise program appears to help relieve the motor symptoms of Parkinson’s disease, a review study suggests. Researchers also observed that older people and those engaging in these programs for longer periods may get the most benefit. The review study, “Effects and parameters of community-based…

Companies Join Forces to Develop Vectorized Antibody Therapies

VectorY Therapeutics and Annogen have announced a new agreement to work toward developing vectorized antibody therapies for Parkinson’s disease and other neurological conditions. “We are delighted to work together with Annogen on novel tailored cell-specific promoters to enhance VectorY’s transformative AAV-vectorized antibody platform and its potential to…

Phase 2b Trial of Mesdopetam Misses Main Goal

A Phase 2b clinical trial testing the investigational oral therapy mesdopetam, which aims to reduce levodopa-induced dyskinesia (involuntary movements) in people with Parkinson’s disease, did not reach its main goal. However, some promising reductions in dyskinesia measures were seen with the treatment. Top-line results from the trial were…